ISOThrive Inc., a microbiome therapeutics company announced that the U.S. Patent and Trademark Office has issued a Composition of Matter and Production Method patent for its first Farmaceutical™ Maltosyl-Isomaltooligosaccharides (MIMO™), a prebiotic for use as an animal feed additive and pet food supplement. USDA and University of GA studies showed MIMO as highly effective at …

George Mason University’s Mason Enterprise is establishing a new network of life science business mentors to help startups across Virginia launch and scale their ventures. The new team of mentors will support a broad range of life science companies in bringing their innovations, including therapeutics, medical devices, diagnostics and software, to market. This network will …

The FDA has established a public docket to solicit comments on several issues related to FDA’s regulation of certain drug products approved under abbreviated new drug applications before the enactment of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. Because these Pre-Hatch-Waxman ANDAs (PANDAs) were submitted under …

Bonumose is pleased to announce that the U.S. Patent & Trademark Office has issued U.S. Patent No. 11,078,506 for “Enzymatic Production of D-Allulose”. This patent issuance follows Bonumose’s Allulose U.S. Patent No. 11,053,528 (July 6, 2021) and allulose U.S. Patent No. 10,704,069 (July 7, 2020). Bonumose has been issued additional Allulose patents and/or has patent …

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it has secured $11.5 million in an oversubscribed equity financing and entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $9 million in term loans, of which an initial $5 million has been funded, …

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, dosed the first two patience in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks to …